Gadobenate and Breastfeeding

Summary of use during lactation

Gadobenate has been safely used in infants, so maternal use does not appear to pose a substantial risk to a breastfed infant.[1] Guidelines developed by North American professional organizations state that breastfeeding need not be disrupted after a nursing mother receives a gadolinium-containing contrast medium.[2-4]

Drug levels in milk and infant serum

Maternal Levels. The manufacturer reports that limited literature indicates that breastfeeding after gadobenate dimeglumine administration to the mother would result in the infant receiving an oral dose of 0.001%-0.04% of the maternal dose. Infant Levels. Relevant published information was not found as of the revision date.

Effects in breastfed infants

Relevant published information was not found as of the revision date.

Effects on lactation and breastmilk

Relevant published information was not found as of the revision date.

Alternative drugs to consider

Gadobutrol, Gadoteridol, Gadoterate

References

1. Fraum TJ, Ludwig DR, Bashir MR, et al. Gadolinium-based contrast agents: A comprehensive risk assessment. J Magn Reson Imaging 2017;46:338-5328083913 PubMed
2. Copel J, El-Sayed Y, Heine RP, et al. Committee Opinion No. 723: Guidelines for diagnostic imaging during pregnancy and lactation. Obstet Gynecol 2017;130:e210-e628937575 PubMed
3. American College of Radiology Committee on Drugs and Contrast Media. Administration of contrast media to breast-feeding mothers. In, ACR manual on contrast media. 2023;Version 2023:120-1. https://www.acr.org/Clinical-Resources/Contrast-Manual
4. Bookwalter CA, McDonald RJ, Packard AT, et al. Contrast media in pregnant and lactating patients, from the AJR special series on contrast media. AJR Am J Roentgenol 2024;224:e243141539046138 PubMed